Business Context and Reporting Period
This Form 8-K is a current report filed by AspenBio Pharma, Inc. (not Riot Platforms, Inc.) on October 7, 2010. The filing addresses a restructuring of the Company's corporate governance structure intended to streamline operations and reduce costs.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on governance changes and director compensation adjustments.
- Non-employee Director Compensation: $1,000 per month in cash.
- Non-executive Chair Compensation (Gail Schoettler): $2,000 per month in cash, effective October 2010.
- Stock Options: Non-employee directors receive annual grants; the Chair receives a grant equal to 1.5 times the standard amount.
- Severance: No severance was paid to Daryl J. Faulkner upon the termination of his employment agreement.
Material Changes Versus Prior Period
Effective October 7, 2010, the following governance changes were implemented:
- Leadership Roles: Gail Schoettler became the non-executive Chair of the Board. Daryl J. Faulkner stepped down from the officer role of Executive Chairman.
- Structural Eliminations: The office of Vice Chairman and the designation of "Lead Director" were eliminated.
- Employment Status: Mr. Faulkner's employment agreement (entered into January 2009) was mutually terminated. He retains health benefits until December 31, 2010, but is no longer an officer.
- Director Continuity: All directors, including Messrs. Faulkner and Pusey, continue to serve on the Board.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of material risks and contingencies. The primary commentary from management indicates the changes were made to reduce costs while retaining the experience of all directors.
Important Facts for Investor Verification
- Verify the distinction between the registrant (AspenBio Pharma, Inc.) and the company name provided in the request metadata (Riot Platforms, Inc.).
- Confirm the termination of Daryl J. Faulkner's employment agreement and the absence of severance payments.
- Note the increase in cash compensation for the Board Chair to $2,000/month compared to $1,000/month for other non-employee directors.
- Confirm that the "Lead Director" role was eliminated in favor of a non-executive Chair.